Floatz logo

Cyclophosphamide

Solid Tumor Cancer

Dragonfly TherapeuticsSmall moleculePhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

42 Active assets in the Solid Tumor Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sarcoma Oncology Research Center, LLC
Phase 2CCC
Zofran
GlaxoSmithKline
Phase 3CCC
DEXAMETHASONE
GlaxoSmithKline
Phase 3CCC
Casopitant
GlaxoSmithKline
Phase 3CCC
Thalidomide
Sarcoma Oncology Research Center, LLC
Phase 2CCC

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →